{"": [121, 130, 0, 131, 1242, 0], "Introduction": [1243, 5432, 0], "Study design": [5456, 6446, 0], "Cells, viruses, and animals": [6447, 7693, 0], "Construction and production of recombinant chimpanzee adenovirus": [7694, 9082, 0], "Western blot": [9083, 9714, 0], "Expression and purification of proteins": [9715, 10664, 0], "Immunization": [10665, 11048, 0], "Enzyme-linked immunosorbent assay (ELISA)": [11049, 12357, 0], "Pseudotyped virus neutralization assay": [12358, 13274, 0], "Live SARS-CoV-2 neutralization assay": [13275, 14105, 0], "Titration of neutralizing activity against variants": [14106, 15090, 0], "AdC7 and human Ad5 neutralization assay": [15091, 15981, 0], "Enzyme-linked immunospot (ELISpot) assay": [15982, 17299, 0], "Intracellular cytokine staining (ICS) and \ufb02ow cytometry": [17300, 18243, 0], "Animal protection against virus challenge": [18244, 18964, 0], "qRT-PCR": [18965, 20176, 0], "Histopathology analysis": [20177, 20639, 0], "Statistical analysis": [20640, 20845, 0], "Materials and methods": [5433, 20845, 1], "Vaccine design and antigen expression": [20855, 21436, 0], "Humoral responses induced by AdC7 vaccines in mice": [21437, 25471, 0], "Cellular responses induced by AdC7 vaccines in mice": [25472, 26973, 0], "Protection efficacy of AdC7-RBD-tr2 against SARS-CoV-2 challenge in mice": [26974, 31243, 0], "Immune responses and protection efficacy conferred by low dose of AdC7-RBD-tr2": [31244, 33622, 0], "Results": [20846, 33622, 1], "Discussion": [33623, 39457, 0], "Supplementary Material": [39458, 39520, 0]}